Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
10 May 1999 and 1 June 1999
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1999
Report date:
1999

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
OECD Guideline 420 (Acute Oral Toxicity - Fixed Dose Method)
Version / remarks:
OECD Guidelines for Testing of Chemicals No. 420 "Acute Oral Toxicity - Fixed Dose Method" (adopted 17 July 1992)
Deviations:
not specified
Qualifier:
according to guideline
Guideline:
EU Method B.1 bis (Acute Oral Toxicity - Fixed Dose Procedure)
Version / remarks:
Method B1 bis in Commission Directive 92/69/EEC (which constitutes Annex V of Council Directive 67/548/EEC).
Deviations:
not specified
GLP compliance:
yes (incl. QA statement)
Test type:
fixed dose procedure
Limit test:
yes

Test material

1
Chemical structure
Reference substance name:
-
EC Number:
437-450-6
EC Name:
-
Cas Number:
64654-05-3
Molecular formula:
Hill formula: C28 H37 N
IUPAC Name:
N-(dodecylphenyl)naphthalen-1-amine
Test material form:
liquid: viscous
Details on test material:
Sponsor's identification: APAN
Description: redbrown viscous liquid
Lot number: EL01010B01/KZ8911.5
Storage conditions: room temperature in the dark
Specific details on test material used for the study:
No further details specified

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
Male and female Sprague-Dawley CD (Crl : CD (SD) IGS BR) strain rats supplied by Charles River (UK) Ltd, Margate, Kent, UK were used. At the start of the study the males weighed 219 to 232g, and the females 201 to 232g, and were eight to twelve weeks old. After a minimum acclimatisation period of at least five days the animals were selected at random and given a number unique within the study by indelible ink marking on the tail and a number written on a cage card.
The animals were housed in groups of up to five by sex in solid-floor polypropylene cages furnished with wood flakes. With the exception of an overnight fast immediately before dosing and for approximately three to four hours after dosing, free access to mains drinking water and food (Rat and Mouse Expanded Diet No.1, Special Diets Services Limited, Witham, Essex, UK) was allowed throughout the study.
The temperature and relative humidity were controlled to remain within target ranges of 19 to 25 °C and 30 to 70% respectively. The rate of air exchange was approximately 15 changes per hour and the lighting was controlled by a time switch to give 12 hours light and 12 hours darkness.

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
arachis oil
Details on oral exposure:
For the purpose of the study the test material was freshly prepared, as required, as a solution in arachis oil BP. The preparations were mixed thoroughly using a vortex mixer.
Doses:
Preliminary Study: 500 & 2000 mg/kg
Main Study (Limit Study): 2000 mg/kg
No. of animals per sex per dose:
Preliminary Study: 1 animal/sex/dose
Main Study: 5 animals/sex
Control animals:
no
Details on study design:
Preliminary Study
Clinical observations were made 1/2, 1, 2, and 4 hours after dosing and then daily for seven days. Morbidity and mortality checks were made twice daily.
Individual bodyweights were recorded on the day of dosing to allow calculation of individual treatment volumes. No necropsies were performed.

Main Study (Limit Study)
Clinical observations were made 1/2, 1, 2, and 4 hours after dosing and subsequently once daily for 14 days.
Individual bodyweights were recorded on Day 0 (the day of dosing) and on Days 1, 2, 3, 7 and 14.
At the end of the study the animals were killed by cervical dislocation and subjected to gross necropsy. This consisted of an external examination and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded. No tissues were retained.
Statistics:
Data evaluations included the relationship, if any, between the animals' exposure to the test material and the incidence and severity of all abnormalities including behavioural and clinical observations, gross lesions, bodyweight changes, mortality and any other toxicological effects. The 'discriminatory dose' was also identified. This is the highest of the four fixed dose levels which can be administered without causing compound-related mortality (including humane kills). If possible the signs of evident toxicity were also identified. Evident toxicity is defined as the toxic effects which are of a severity such that administration at the next highest level could result in mortality.

Results and discussion

Preliminary study:
There were no deaths at dose levels of 500 and 2000 mg/kg bodyweight.
Clinical signs of toxicity noted in animals treated with 2000 mg/kg were piloerection and/or hunched posture.
Based on this information, a dose level of 2000 mg/kg bodyweight was selected for the main study.
Effect levelsopen allclose all
Key result
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Key result
Sex:
male/female
Dose descriptor:
discriminating dose
Effect level:
2 000 mg/kg bw
Based on:
test mat.
Mortality:
There were no deaths.
Clinical signs:
Hunched posture was noted in three female animals during the day of dosing and/or one day after dosing. No other clinical signs of toxicity were noted during the study.
Body weight:
All animals showed expected gains in bodyweight over the 14-day study period.
Gross pathology:
No abnormalities were noted at necropsy.
Other findings:
No further findings noted in the study report.

Any other information on results incl. tables

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA IN THE PRELIMINARY STUDY

DOSE LEVEL

mg/kg

Animal Number and Sex

Hours Post Dosing (Day 0)

Day Number

½

1

2

4

1

2

3

4

5

6

7

500

1-0 Male

0

0

0

0

0

0

0

0

0

0

0

2-0 Female

0

0

0

0

0

0

0

0

0

0

0

2000

3-0 Male

0

0

0

HP

H

0

0

0

0

0

0

4-0 Female

0

0

0

H

H

0

0

0

0

0

0

0 = no signs of systemic toxicity

H = hunched posture

P = pilo-erection

 

INDIVIDUAL CLINICAL OBSERVATIONS AND MORTALITY DATA IN THE LIMIT STUDY

DOSE LEVEL mg/kg

Animal Number and Sex

Hours Post Dosing (Day 0)

Day Number

½

1

2

4

1

2

3

4

5

6

7

8

9

10

11

12

13

14

2000

5-0 Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

5-1 Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

5-2 Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

5-3 Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

5-4 Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6-0 Female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6-1 Female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6-2 Female

0

0

0

H

H

0

0

0

0

0

0

0

0

0

0

0

0

0

6-3 Female

0

0

H

H

H

0

0

0

0

0

0

0

0

0

0

0

0

0

6-4 Female

0

0

0

0

H

0

0

0

0

0

0

0

0

0

0

0

0

0

0 = no signs of systemic toxicity

H = hunched posture

 

INDIVIDUAL BODYWEIGHTS AND BODYWEIGHT CHANGES IN THE LIMIT STUDY

DOSE LEVEL mg/kg

Animal Number and Sex

Bodyweight (g) at Day

Increment (g) During Days

0

1

2

3

7

14

0-1

1-2

2-3

3-7

7-14

2000

5-0 Male

5-1 Male

5-2 Male

5-3 Male

5-4 Male

6-0 Female

6-1 Female

6-2 Female

6-3 Female

6-4 Female

219

223

232

222

224

209

232

201

229

224

224

230

242

226

228

212

239

203

235

229

232

243

258

234

240

220

251

208

248

238

235

248

262

238

244

221

245

208

249

236

252

280

300

270

275

233

268

216

267

249

293

323

354

308

311

245

292

218

303

272

5

7

10

4

4

3

7

2

6

5

8

13

16

8

12

8

12

5

12

9

3

5

4

4

4

1

6

0

1

-2

17

32

38

32

31

12

23

8

18

13

41

43

54

38

36

12

24

2

36

23

 

INDIVIDUAL NECROPSY FINDINGS IN THE LIMIT STUDY

DOSE LEVEL

mg/kg

Animal Number and Sex

Time of Death

Macroscopic Observations

2000

5-0 Male

5-1 Male

5-2 Male

5-3 Male

5-4 Male

6-0 Female

6-1 Female

6-2 Female

6-3 Female

6-4 Female

Killed Day 14

Killed Day 14

Killed Day 14

Killed Day 14

Killed Day 14

Killed Day 14

Killed Day 14

Killed Day 14

Killed Day 14

Killed Day 14

No abnormalities detected

No abnormalities detected

No abnormalities detected

No abnormalities detected

No abnormalities detected

No abnormalities detected

No abnormalities detected

No abnormalities detected

No abnormalities detected

No abnormalities detected

 

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
The discriminatory dose was identified as 2000 mg/kg bodyweight.
The acute oral median lethal dose (LD50) of the test material, APAN, in the Sprague-Dawley CD strain rat was estimated to be greater than 2000 mg/kg bodyweight.
The test material was considered to have no significant acute toxic risk if swallowed and did not meet the criteria for classification under EC labelling regulations. No symbol or risk phrase are required.
Executive summary:

A study was performed to assess the acute oral toxicity of the test material in the Sprague-Dawley CD strain rat. The method complied with that described in the OECD Guidelines for Testing of Chemicals No. 420 "Acute Oral Toxicity – Fixed Dose Method" (adopted 1 7 July 1 992) and Method B 1 bis in Commission Directive 92/69/EEC (which constitutes Annex V of Council Directive 67/548/EEC).

 

The results may be used as a basis for classification and labelling under Annex VI of Council Directive 67/548/EEC (adapted to technical progress by Commission Directive 93/21/EEC) relating to the classification, packaging and labelling of dangerous substances.

 

Following a preliminary study in which there were no deaths at dose levels of 500 and 2000 mg/kg, a group of ten fasted animals (five males and five females) was given a single oral dose of test material, as a solution in arachis oil BP at a dose level of 2000 mg/kg bodyweight. The animals were observed for fourteen days after the day of dosing and were then killed and subjected to gross necropsy.

 

There were no deaths. Hunched posture was noted in three female animals. No other clinical signs of toxicity were noted during the study.

 

All animals showed expected gains in bodyweight during the 14-day study period.

 

No abnormalities were noted at necropsy.

 

The discriminatory dose was identified as 2000 mg/kg bodyweight.

 

The acute oral median lethal dose (LD50) of the test material in the Sprague-Dawley CD strain rat was estimated to be greater than 2000 mg/kg bodyweight. The test material was considered to have no significant acute toxic risk if swallowed and did not meet the criteria for classification under EC labelling regulations. No symbol or risk phrase are required.